EP1689365A1 - Vecteurs d'administration de medicaments et leurs applications - Google Patents

Vecteurs d'administration de medicaments et leurs applications

Info

Publication number
EP1689365A1
EP1689365A1 EP04819663A EP04819663A EP1689365A1 EP 1689365 A1 EP1689365 A1 EP 1689365A1 EP 04819663 A EP04819663 A EP 04819663A EP 04819663 A EP04819663 A EP 04819663A EP 1689365 A1 EP1689365 A1 EP 1689365A1
Authority
EP
European Patent Office
Prior art keywords
liposome
mol
liposomes
lipid
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04819663A
Other languages
German (de)
English (en)
Inventor
Rolf Müller
Thomas Nahde
Sabine MÜLLER-BRÜSSELBACH
Andreas Graser
Tanja Hilka
Peter Höllig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affitech AS
Original Assignee
Affitech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affitech AS filed Critical Affitech AS
Priority to EP04819663A priority Critical patent/EP1689365A1/fr
Publication of EP1689365A1 publication Critical patent/EP1689365A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to novel drug delivery vehicles comprising cholesterol and sphingomyelin, methods for making and using them, in particular for the treatment of proliferative diseases, immune diseases, infectious diseases, vascular diseases, rheumatoid diseases and inflammatory diseases.
  • free form also comprises chemical derivatives of a given drug as well as various addition salts that can be formed with the drug.
  • attachment of a drug to or the incorporation of a drug into a delivery vehicle can offer advantages if compared to the administration of the drug in its free form.
  • factors, which influence the overall efficacy of a given drug can be advantageously affected by incorporation into or attachment to such a vehicle. These factors include tissue specific distribution, in particular preferential accumulation in a certain tissue of interest or at a disease site, targeting of the drug to a particular cell type, decrease of interaction with blood components and increase in circulation time.
  • the above factors are important but among such delivery vehicles also factors such as the release characteristic of the drug from the vehicle become important for their efficacy. While all of these factors will contribute to some degree to a potential improvement of the efficacy of a given drug, when attached to or incorporated into such a drug delivery vehicle, the ultimate test for a novel delivery vehicle is its efficacy in a disease animal model or in a patient when compared to the drug in its "free form" or to another vehicle.
  • liposomal formulations generally refers to uni- or multilamellar lipid structures enclosing an aqueous interior, depending on the number of lipid membranes formed.
  • liposomes can be loaded with drugs, i.e. the drug is encapsulated in the interior of the liposome, and/or drugs can be attached to the liposome or incorporated into the lipid bilayer.
  • drugs i.e. the drug is encapsulated in the interior of the liposome, and/or drugs can be attached to the liposome or incorporated into the lipid bilayer.
  • Such drug comprising liposomal formulations have been shown to have an increased efficacy in comparison to the free drug.
  • a liposomal formulation including the vinca alkaloid vincristine has a greater efficacy against leukemia cells, if compared to free vincristine and that it shows a reduced overall toxicity (Mayer et al (1993) Cancer Chemo. Pharmacol. 33: 17-24). Since liposomes can be formed of almost any lipid a large variety of different liposomal formulations are known in the art. However, very little is known about the influence that individual lipids will have on the efficacy of a drug for a given disease let alone which molar ratios of two or more different lipids will lead to lipid compositions with an improved efficacy.
  • EP 0 555 333 Bl describes liposomes with a high cholesterol content.
  • the liposomes comprise cholesterol and phospholipids in a cholesterokphospholipid ratio of 0.8 to 1.2. It is taught that these vesicles are suitable for the delivery of antigens to elicit an antigenic response, i.e. the use as a vaccine is disclosed.
  • US 5,543,152, US 5,471,516, and US 5,814,335 teach the use of liposomal formulations comprising sphingomyelin (SM) and cholesterol (CH) and in particular liposomes comprising between 30 and 75 mol% sphingomyelin and between 25 and 50 mol% cholesterol, which are called sphingosomes, for the delivery of drugs.
  • SM sphingomyelin
  • CH cholesterol
  • sphingosomes for the delivery of drugs.
  • liposomes it is taught that they possess an increased acid stability, if compared to liposomes comprising, for example, distearoyl-phosphatidylcholine (DSPC) instead of SM.
  • DSPC distearoyl-phosphatidylcholine
  • the present invention therefore, provides a liposome, wherein CH and SM are present in relation to the total molar lipid composition of the liposome at a molar ratio of about 30 to about 60 mol% and about 5 to about 20 mol%, respectively. It has been found that a concentration of above 60 mol% limits the formation of regular lipid bilayer structures and, therefore, a content of 60% CH is the upper limit for the liposomes of the present invention. On the other hand lowering the cholesterol concentration below 30 mol% appears to increase the rate of elimination of the liposomes form the circulation and, thus, decreases the biological half life of a drug, comprised in the liposome. Concomitantly the efficacy of the liposomes in therapeutic applications, in particular in tumor therapy decreases.
  • an increase of SM over 20 mol% to, for example, 30 mol% reduces the efficacy of doxorubicin in an animal tumor model, while reduction of SM below 5% or complete omission of SM dramatically decreases the circulation time of encapsulated doxorubicin and in turn reduces efficacy.
  • the present invention was made in part through a thorough analysis of the influence that the variation of different constituents of a liposome has on the efficacy of a drug and the surprising discovery that by substantial lowering the SM content, if compared to prior art liposomes, in a liposome with a high cholesterol content a liposome is obtained that exhibits a stable liposomal structure with an improved drug delivery and therapeutic efficacy.
  • SM is present in relation to the total molar lipid composition of the liposome at a molar ratio of about 8 to about 19 mol%, more preferably about 10 to about 18 mol%, even more preferably about 12 to about 16 mol% and most preferably about 13 to about 15 mol%.
  • CH is present in relation to the total molar lipid composition of the liposome at a molar ratio of about 35 to about 58 mol%, more preferably of about 40 to 56 mol%, even more preferably of about 45 to about 54 mol% and most preferably of about 48 to about 52 mol%.
  • the liposome comprises in relation to the total molar lipid composition CH and SM at a molar ratio of about 35 to about 58 mol% and of about 5 to 20 mol%, preferably of about 40 to about 58 mol% and of about 8 to about 19 mol%, respectively, and more preferably of about 45 to about 54 mol% and of about 10 to about 18 mol%, respectively, and most preferably of about 48 to about 52 mol% and of about 12 to about 16 mol%, respectively.
  • the remainder of the lipid i.e. the amount of lipid which is neither SM nor CH and which is needed to add up to 100 mol% can be made up of any lipid.
  • lipid refers to any substance having fatty or fat-like properties.
  • a lipid comprises an extended apolar residue (X) and usually a water soluble, polar, hydrophilic residue (Y), which can be characterized by the basic formula
  • n equals or is greater than zero.
  • Preferred lipids, which can make up the remainder of the lipids in the liposomes of the present invention are selected from the group consisting of glycerides, glycerophospholipides, glycerophosphinolipids, glycerophosphonolipids, sulfolipids, sphingolipids, phospholipids, isoprenolides, steroids, stearines, steroles and carbohydrate containing lipids.
  • the remainder of the lipids preferably comprises one or more phospholipids.
  • the phospholipid is selected from the group consisting of phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE).
  • PC phosphatidylcholine
  • PS phosphatidylserine
  • PE phosphatidylethanolamine
  • the lipids of the liposome of the present invention only consist of SM, CH and phospholipids. In this case SM and/or CH can be present in their preferred and particularly preferred concentration ranges indicated above.
  • the liposome of the present invention comprises PE and in a preferred embodiment the PE is present in relation to the total molar lipid composition of the liposome at a molar ratio of about 5 to about 25 mol%, preferably about 10 to about 20 mol% and more preferably about 12 to about 18 mol% and most preferably about 14 to about 16 mol%.
  • these ratios of PE are present when at the same time SM and/or CH are comprised in the liposome in its preferred and particular preferred concentration ranges indicated above and the remainder of the lipid is made up of any lipid as defined above, however, in a particularly preferred embodiment the remainder of the lipid is selected from a phospholipid.
  • a further component, which can be comprised in the liposome of the present invention is PC.
  • PC in a preferred embodiment makes up between about 15 and about 40 mol% in relation to the total molar lipid composition of the liposome. More preferably the liposome of the present invention comprises between about 20 to about 35 mol% PC.
  • the liposome consists of SM, CH, PE and PC and SM, CH and PE are present in their preferred and particular preferred concentration ranges as outlined above and the remainder of the lipid up to 100 mol% is made up of PC.
  • Liposomes of the present invention can have a diameter between 10 and 1000 nm. They, however, have in a preferred embodiment a diameter of between 50 and 200 nm and more preferably between 80 and 150 nm.
  • the diameter of the liposomes can be affected, for example, by extrusion of the liposomal composition through sieves or meshes with a known pore size. This and further methods of controlling the size are well known in the art and are described, for example, in Mayhew et al. (1984) Biochim. Biophys. Acta 775:169- 174 or Olson et al. (1979) Biochim. Biophys. Acta 557:9-23.
  • SM is a collective term for lipids sharing a similar hydrophilic head group. However, many different apolar residues can be attached to this head group. Thus, SM isolated from different natural sources varies substantially in the length and chemical structure of the attached apolar residues and usually is a mixture of different SMs. It has been observed by the present inventors that certain SMs provide a particular good efficacy, therefore, the SM employed in the liposomes of the present invention is preferably selected from the group consisting of SM derived from milk, SM derived from egg yolk, SM derived from brain, and synthetic SM. Synthetic SM has in a preferred embodiment the SM is distearoyl-SM.
  • the PE is selected from the group consisting of PE derived from egg; PE derived from heart; PE derived from liver; PE derived from plant; PE derived from bacteria; and synthetic PE, in particular l,2-diacyl-sn-glycero-3-PE, l-acyl-2-acyl-sn- glycero-3-PE and/or l,2-dilauroyl-sn-glycero-3-PE (DLPE).
  • any of the components making up the membrane of the liposomes of the present invention can be attached to a further chemical moiety.
  • the term chemical moiety is not particular limited. However, in preferred embodiments the chemical moiety is a targeting moiety as discussed in more detail below or a stabilizing moiety. Stabilizing moieties within the meaning of this invention increase the circulation time of the liposome once it is administered. Particular preferred stabilizing moieties are ganglioside GM1, phosphatidylinositol or PEG, particular preferred PEGs have a molecular mass between about 1,000 and about 10,000 g/mol, more preferably about 5,000 g/mol.
  • the chemical moieties in particular the stabilizing moieties are attached to only a fraction of the molecules making up the membrane of the liposomes. It is preferred that between about 1 to about 20 mol% of the components of the liposomal membrane carry an attached chemical moiety, more preferably between about 3 and about 10 mol% and even more preferably about 5 mol%.
  • a preferred liposomal component for attachment of the chemical moiety, in particular for the stabilizing moiety is a lipid component. While different chemical moieties can be attached to different lipid components it is preferred that the chemical moiety(ies) is(are) attached to one or more of the phospholipids comprised within the liposome of the present invention. In a further preferred embodiment the one or more chemical moiety is attached to PE. In particular, if a stabilizing agent like, for example, PEG is used PE is used for attachment.
  • proteins and peptides can be incorporated into the liposome for stabilizing the lipid bilayers of the liposomes of the present invention.
  • Detergents which can be used as bilayer stabilizing components include, but are not limited to, Triton X-100, deoxycholate, octylglucoside and lyso- phosphatidylcholine.
  • Proteins which can be used as bilayer stabilizing components include, but are not limited to, glycophorin and cytochrome oxidase.
  • a liposome can comprise between 0.05 and 15 mol% of a stabilizing agent.
  • the liposomes of the present invention do not appear to exhibit a particular preference for binding to certain tumor cells.
  • a means of targeting of the liposome of the present invention which allows targeting of the liposomes primarily to a specific site with in the body can decrease the systemic toxicity of the liposomal drug formulation or alternatively allows to administer higher amounts of a drug at the same level of toxicity. Therefore, in a further embodiment of the liposomes of the present invention a targeting moiety is attached to the liposome. As outlined above with respect to the chemical moiety in principal the targeting moiety can be attached to any component of the liposome.
  • the targeting moiety is: a) attached to one of the lipid components of the liposome, b) attached to a membrane protein which can be incorporated into the membrane of the liposomes of the present invention or c) is itself capable of insertion or integration in the lipid layer.
  • attachment refers to a direct or indirect, covalent or non-covalent bond and connection, respectively, between a chemical moiety in particular a targeting moiety and another component of the liposome.
  • a wide variety of chemical groups which allow attachment as defined above are known in the art including, for example, biotin-streptavidin, amino-reactive groups (e.g. carbodiimides, hydroxylmethylphosphine, imidoester, N-hydroxysuccinimide esters, isothiocyanates, isocyanates), sulfhydryl-reactive groups (e.g.
  • carboxyl-reactive molecules e.g. carbodiimides, carbodiimidazole, diaoalkanes
  • hydroxyl-reactive groups e.g. carbonyldiimidazole, alkyl halogens, isocyanates
  • the targeting moiety is selected from the group consisting of a peptide or protein, in particular an antibody or fragment thereof, a single-chain antibody or fragment thereof, a receptor ligand or fragment thereof; a carbohydrate; and a ligand.
  • the targeting moiety can be selected from the group consisting of natural or synthetic receptor-binding peptides, in particular integrin-binding peptides such as RGD-comprising peptides; growth factors, in particular VEGF, EGF, PDGF, TGF ⁇ , TGF ⁇ , KGF, SDGF, FGF, IGF, HGF, NGF, BDNF, neurotrophine, BMF, bombesin, M- CSF, GM-CSF, thrombopoietin, erythropoietin, SCF, SDGF, oncostatin, PDEGF, endothelin; cytokines, in particular IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL- 10, IL-12, IL-13, IL-14, IL-15, interferon , ⁇ or ⁇ , tumor necrosis factors such as TNF ⁇ , TNF ⁇ ; chemok
  • the targeting moiety is attached to a spacer.
  • spacer refers to a chemical moiety, which serves the purpose of providing better accessibility of the targeting moiety even when it is attached to a component of the liposome, e.g. a lipid of the present invention which might otherwise sterically hinder the binding of the targeting moiety to its respective target structure.
  • Spacers within this meaning have a linear extension of at least 0.5 nm preferably the spacer has a linear extension of between 1 and 10 nm and even more preferably between 2 and 5 nm.
  • the spacer is preferably a linear or branched saturated or unsaturated carbohydrate chain.
  • the carbohydrate chain preferably comprises multimeric repeats of a monomeric building block.
  • the spacer is hydrophilic.
  • the spacer can comprise a functional group which allows attachment to the targeting moiety on one terminus and another functional group on the other terminus, which allows attachment of the spacer to a component of the liposome, e.g. a lipid of the present invention.
  • Preferred spacers are bifunctional molecules, in particular, bifunctional polyethylene or polypropylene glycol derivatives comprising preferably between about 1 and 40 repeat units, oligopeptides comprising natural and/or synthetic amino acids.
  • the oligopeptides preferably comprise between 1 and 40, preferably between 2 and 20 and more preferably between 2 and 10 amino acids.
  • a particular preferred building block of a spacer is 8- amino-3, 6-dioxatanoic acid (doo) and spacers comprising between 1 to 10 repeat units of doo are preferred. Spacers comprising between 2 and 5 doo units are even more preferred and spacers comprising 3 doo units are most preferred.
  • the spacer has a length of between 1 and 10 nm, preferably between 2.5 and 5 nm.
  • the targeting moiety is attached to a lipid, preferably a phospholipid like, for example PE, PC or PS and preferably the lipid, which is used for attachment of a targeting moiety is selected from the group consisting of N-caproylamine-PE, N-dodecanylamine-PE, phophatidylthioethanol, N-[4- (p-maleimidomethyl)cyclohexane-carboxamide-PE (N-MCC-PE), N-[4-(p- maleimidophenyl)butyramide]-PE (N-MPB), N-[3-(2-pyridyldithio)propionate]-PE (N- PDP), N-succinyl-PE, N-glutaryl-PE, N-dodecanyl-PE, N-biotinyl-PE, N-biotinyl-cap-PE, phosphatidyl-(ehtyl)
  • the membrane of the liposomes can further comprise components, which are capable of insertion/integration into the lipid layer.
  • components are proteins with a hydrophilic portion, including one or more membrane spanning domains or GPI-anchor, or other amphipathic molecules such as lipopeptides and glycolipids or molecules conjugated or fused to one or more fatty acid, lipid or other hydrophobic moieties.
  • proteins with a hydrophilic portion including one or more membrane spanning domains or GPI-anchor, or other amphipathic molecules such as lipopeptides and glycolipids or molecules conjugated or fused to one or more fatty acid, lipid or other hydrophobic moieties.
  • Such molecules can, for example, provide the liposome with a targeting capacity, i.e. can be a targeting moiety, or can have an enzymatic function.
  • the liposomes of the present invention are superior vehicles for drugs that were shown to provide a prolonged presence of the drug in the circulation if compared to the free drug, a good release characteristics, i.e. a release of the drug from the liposome into the circulation, a low binding to blood components and a good stability against conditions of high or low pH, which are encountered, for example, during production of the liposomes.
  • a good release characteristics i.e. a release of the drug from the liposome into the circulation
  • a low binding to blood components i.e. a release of the drug from the liposome into the circulation
  • a low binding to blood components i.e. a release of the drug from the liposome into the circulation
  • a low binding to blood components i.e. a release of the drug from the liposome into the circulation
  • a low binding to blood components i.e. a release of the drug from the liposome into the circulation
  • a low binding to blood components i.e. a
  • the liposomes of the present invention are superior delivery vehicles the liposomes of the present invention comprise in a preferred aspect at least one drug and/or at least one diagnostic.
  • a drug within the meaning of the present invention is any compound, which exerts a therapeutic effect upon administration.
  • the drug or diagnostic is comprised in the interior of the liposome or in cases of lipophilic drugs also within or between the lipid bilayers.
  • a variety of methods are available in the prior art to "load" a liposome with a given drug or diagnostic.
  • the drug and/or diagnostic is/are admixed with the lipid components during formation of the liposomes.
  • Other passive loading methods include dehydration-rehydration (Kirby & Gregoriadis (1984) Biotechnology 2:979), revers-phase evaporation (Szoka & Papahadjopoulos (1978) Proc. Natl.Acad. Sci. USA 75:4194-), or detergent-depeletion (Milsmann et al. (1978) Biochim. Biophys. Acta 512:147-155).
  • these techniques often lead to a substantial loss of drug during loading, which is a particular disadvantage in cases where the drug is expensive.
  • encapsulating drugs and/or diagnostics include so called “remote loading” or “active loading” in which due to a gradient, for example, a pH or salt gradient between the exterior and the interior of a preformed liposome the drug and/or diagnostic is transported into the liposome along the gradient (see, for example Cheung et al. (1998) Biochim. Biophys. Acta 1414:205-216; Cullis et al. (1991) Trends Biotechnol. 9:268-272; Mayer et al. (1986) Chem. Phys. Lipids 40:333-345).
  • the passive and active loading techniques referred to above and other methods well known in the art can all without limitation employed by the skilled artisan.
  • the most efficient method of loading for any given drug or diagnostic can be determined by routine experimentations by well established procedures. Variables which are typically adjusted are pH, temperature, salt type and concentration, type of buffer etc.
  • the drugs and/or diagnostics are loaded by remote loading into the liposomes, since this method offers a very low loss of the substance to be loaded.
  • a pH gradient is used for loading.
  • the interior of the liposome will typically be acidified with respect to its exterior.
  • the interior will have a pH between 1 and 6 prior to loading with the drug or diagnostic.
  • the drug is selected from the group consisting of analgesics, antirheumatics, antheiminthics, antiallergics, antianemics, antiarrhythmics, antibiotics, angiogenesis inhibitors, antiinfectives, antidemenics (nootropics), antidiabetics, antidotes, antiemetics, antivertiginosics, antiepileptics, antihe orrhagics, antihypertonics, antihypotonics, anticoagulants, antimycotics, antitussiv agents, antiviral agents, beta- receptor and calcium channel antagonists, broncholytic and antiastmatic agent, chemokines, cytokines, mitogens, cytostatics, cytotoxic agents and prodrugs thereof, dermatics, hypnotics and sedatives, immunosuppressants, immunostimulants, peptide or protein drugs, in particular hormones and physiological or pharmacological inhibitors of mitogens, chemok
  • the liposomes of the present invention are particularly suited for the therapy of proliferative diseases in which an inhibition of the cellular proliferation needs to be achieved, therefore, the liposome can comprise any cytostatic or cytotoxic drug, however, from the known cytostatics and cytotoxic drugs the following are particularly preferred: alkylating substances, anti-metabolites, antibiotics, epothilones, nuclear receptor agonists and antagonists, anti-androgenes, anti-estrogens, platinum compounds, hormones and antihormones, interferons and inhibitors of cell cycle-dependent protein kinases (CDKs), inhibitors of cyclooxygenases and/or lipoxygenases, biogeneic fatty acids and fatty acid derivatives, including prostanoids and leukotrienes, inhibitors of protein kinases, inhibitors of protein phosphatases, inhibitors of lipid kinases, platinum coordination complexes, ethyleneimenes, methylmelamines,
  • cytostatic and/or cytotoxic drug is comprised in a liposome of the present invention.
  • the liposomes of the present invention can comprise anti-angiogenic drugs like, for example, fumagillin analogs, thalidomide, 2-methoxyestradiol, protein tyrosine kinase inhibitors.
  • Such drugs are preferred for the treatment of diseases involving activated and/or proliferating endothelial cells
  • cytostatic or cytotoxic drugs in particular those, which are indicated as preferred cytostatic or cytotoxic drugs above.
  • immunosuppressant comprises both substances which lower the activity of immune response as well as substances with an anti-inflammatory action
  • preferred examples are glucocorticoids, in particular beclomethasone, betamethasone, clocortolone, cloprednol, cortisone, dexamethasone, fludrocortisone, fludroxycortide, flumetasone, fiuocinolone acetonide, fluocinonide, fluocortolone, fluorometholone, fluprednidene acetate, hydrocortisone, paramethasone, prednisolone, prednisone, prednylidene, pregnenolone, triamcinolone or triamcinolone acetonide, a cyclosporin, in particular cyclosporin A, mycophenolate mofetil, tacroiimus, rapamycin, FK 506, cycloheximide-N
  • immunosenor encompasses all substances, which influence the function of cells which are involved directly or indirectly in mediation of the immune response, and where the influence leads to an immune response.
  • cells include, for example, macrophages, Langerhans cells and other dendritic cells, lymphocytes, indeterminate cells, but also cells which do not themselves belong to the immune system but are involved in immune disorders of the skin, such as fibroblasts, keratinocytes and melanocytes, but especially Langerhans cells.
  • the strength of the immune response can be determined for example through the amount of cytokines produced (such as interferon-gamma), detection of activation markers on dendritic cells (such as MHCII or CD 86) or the number of activated CD8-positive T cells in the skin.
  • cytokines produced such as interferon-gamma
  • detection of activation markers on dendritic cells such as MHCII or CD 86
  • the number of activated CD8-positive T cells in the skin can be determined for example through the amount of cytokines produced (such as interferon-gamma), detection of activation markers on dendritic cells (such as MHCII or CD 86) or the number of activated CD8-positive T cells in the skin.
  • Immunostimulants for the purpose of the present invention are, in particular, plant immunostimulants which are obtained, for example, from Echinacea pallida or Echinacea purpurea, cytokines such as, for example, interleukins, interferons and colony-stimulating factors, and bacterial constituents or molecules which mimic the latter [such as bacterial DNA and unmethylated oligodeoxynucleotides with CpG sequences, and constituents of the bacterial cell wall or coat, especially the lipopolysaccharides and molecules derived therefrom, such as monophosphoryl-lipid A, muramyldipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine), and/or PamCys3, and other molecules such as tetanus toxoid, poly-L-arginine or MHCII peptides].
  • cytokines such as, for example, interleukins, interferons and colony-sti
  • antibiotics encompasses, for example, penicillins, cephalosporins, tetracyclines, aminoglycosides, macrolide antibiotics, Hncosamides, gyrase inhibitors, sulfonamides, trimethoprim, polypeptide antibiotics, nitroimidazole derivatives, amphenicol, in particular actinomycin, alamethicin, alexidine, 6-aminopenicillanic acid, amoxicillin, amphotericin, ampicillin, anisomycin, antiamoebin, antimycin, aphidicolin, azidamfenicol, azidocillin, bacitracin, beclomethasone, benzathine, benzylpenicillin, bleomycin, bleomycin sulfate, calcium ionophore A23187, capreomycin, carbenicillin, cefacetrile, cefaclor, cefamandole nafate, cefazolin
  • antiinfectives encompasses, for example, antimycotics, agents with antiparasitic effect and virustatics, in particular amphotericin, vifonazole, buclosamide, quinoline sulfate, chlormidazole, chlorphenesin, chlorquinaldol, clodantoin, cloxiquine, cyclopirox olamine, dequalinium chloride, dimazole, fenticlor, flucytosine, griseofulvin, ketoconazole, miconazole, natamycin, sulbentine, tioconazole, toinaftate, antiretroviral agents and/or herpes remedies.
  • antiallergics encompasses, for example, substances from the class of globulins, corticoids or antihistamines, in particular beclomethasone and derivatives thereof, betamethasone cortisone and derivatives thereof, dexamethasone and derivatives thereof, bamipine acetate, buclizine, clemastine, clemizole, cromoglicic acid, cyproheptadine, diflucortolone valerate, dimetotiazine, diphenhydramine, diphenylpyraline, ephedrine, fluocinolone, histapyrrodine, isothipendyl, methdilazine, oxomemazine, paramethasone, prednylidene, theophylline, and/or tolpropamine tritoqualine.
  • mitogens encompass, for example, interferon- alpha, interferon-beta, interferon-gamma, interleukin-1, interleukin-2, interleukin-7, interleukin-10, interleukin-12, interleukin-18, GM-CSF, MIP-1 -alpha/beta, RANTES, EGF, basic or acidic FGF, PDGF, IGF, VEGF, TGF-beta and/or TNF-alpha.
  • mitogens encompass, for example, interferon- alpha, interferon-beta, interferon-gamma, interleukin-1, interleukin-2, interleukin-7, interleukin-10, interleukin-12, interleukin-18, GM-CSF, MIP-1 -alpha/beta, RANTES, EGF, basic or acidic FGF, PDGF, IGF, VEGF, TGF-beta and/or TNF-alpha.
  • the term "dermatics” encompasses, for example, shale oil sulfonates, tar and tar derivatives, astringents, antihidrotics, acne remedies, antipsoriatics, antiseborrheic agents and/or enzyme preparations for the treatment of skin defects.
  • the liposomes of the present invention show an advantageous release pattern thy can also be used to deliver a diagnostic to a certain tissue.
  • a targeting moiety which preferentially localizes the liposomes of the present invention in certain tissues or disease sites.
  • the diagnostic is selected from the group consisting of an electron dense molecule, a paramagnetic molecule, a superparamagnetic molecule, a radioactive molecule, a non-radionitroe isotope, and a fluorescent molecule.
  • the term "marker” refers to a chemical moiety which is directly or indirectly detectable by analytical methods including measurement of fluorescence, nuclear magnetic resonance,
  • - ' computer tomography or scintigrams comprises without limitation electron dense molecules, paramagnetic molecules, superparamagnetic molecules, radioactive molecules like, for example, 13 N, 15 O, 18 F, 51 Gr, 5 Fe, 60 Co, 67 Ga, 75 Se, 99m Tc, U1 ln, u2m Ag, 113m In, I23 I, 1 3 Xe, 148 Au, 35 S, 33 P, 32 P, or n C, non-radioactive isotopes, which include, for example, 2 H and 13 C, and fluorescent molecules or molecules generating fluorescence or light emission like, for example, green fluorescent protein, luciferase, and a variety of fluorescent dies all of which are well known to someone of skill in the art.
  • fluorescent molecules or molecules generating fluorescence or light emission like, for example, green fluorescent protein, luciferase, and a variety of fluorescent dies all of which are well known to someone of skill in the art.
  • the liposome can comprise a variety of additional substances preferably in the membrane or in the interior of stabilizers, protectants, metal ion chelators, buffers and/or additives are comprised in the liposome.
  • the liposomes of the present invention are stable structures, which can, for example, be filtered after production to remove surrounding drug or buffer.
  • the pure liposomes with or without drugs and/or diagnostics can be used, however, due to its stability it is also possible to remove any liquid from the liposome to facilitate easy storage. Therefore, the liposomes. of the present invention can be supplied in dried form, preferably in a freeze dried form. These liposomes can than be readily rehydrated upon addition of water or buffer at the time of use.
  • a further aspect of the present invention is a method for producing a liposome of the . present invention, in which SM, CH and remaining lipid(s) or other components are mixed.
  • the remaining lipid is selected from PE and/or PC. If no drugs or diagnostics are mixed initially with the lipids drugs and/or diagnostics are then in a second step loaded into the liposomes, Since "remote loading" is a preferred way of introducing a substance preferably a drug and/or diagnostic into the liposome the method of the present invention can in a preferred embodiment involve a remote loading step, preferably employing a pH gradient.
  • a further aspect of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a liposome of the present invention or a liposome produced according to the method of the present invention, further comprising stabilizers, protectants, metal ion chelators, buffers and/or additives.
  • a further aspect is a diagnostic composition
  • the liposomes of the present invention, the pharmaceutical composition of the present invention or the diagnostic composition of the present invention preferably comprise, stabilizers which are selected from the group consisting of ⁇ -tocopherol, vitamin E or carbohydrates, in particular glucose, sorbitol, sucrose, maltose, trehalose, lactose, cellubiose, raffinose, maltotriose, or dextran.
  • stabilizers which are selected from the group consisting of ⁇ -tocopherol, vitamin E or carbohydrates, in particular glucose, sorbitol, sucrose, maltose, trehalose, lactose, cellubiose, raffinose, maltotriose, or dextran.
  • the liposomes and liposomal compositions disclosed herein are particular capable delivery vehicles or a pharmaceutical composition of the present invention for the production of a medicament for the therapy of proliferative diseases, immune diseases, in particular autoimmune disease, infectious diseases, vascular diseases, rheumatoid diseases, in particular osteoarthritis or rheumatoid arthritis, inflammatory diseases or any disease or condition, which is associated with the damage or a permeability increase of the vasculature, including but not limited to mechanic injury stroke or hemorrhages.
  • the drugs and/or diagnostics comprised in the liposomes of the present invention can be administered to patients in amounts similar or identical to the amounts in which the free drugs or diagnostics are typically administered.
  • doxorubicin is typically administered in a range from 45 to 75 mg/m 2 per day every 3 to 4 weeks or 10 to 20 mg/m 2 weekly. However, it is also within the capabilities of the attending physician to increase or decrease the dose or administration frequency of the respective drug comprised in the liposome based on the level of toxicity observed.
  • the liposomes or pharmaceutical compositions can be administered through a variety of ways including intra-rnuscular, intravenous, intranasal, intraperitoneal, intradermal, or subcutan.
  • the compounds can also be injected directly into the disease site.
  • Further experiments performed by the present inventors have shown that the liposomes and pharmaceutical compositions have a superior efficacy in the treatment of tumors and, therefore, in a preferred embodiment the proliferative disease is selected from the group consisting of carcinomas of the gastrointestinal or colorectal tract, liver, pancreas, kidney, bladder, prostate, endometrium, ovary, testes, melanoma, dysplastic oral mucosa, invasive oral cancers, small cell and non-small cell lung carcinomas, hormone-dependent breast cancers, independent breast cancers, transitional and squamous cell cancers, neurological malignancies including neuroblastoma, gliomas, astrocytomas, osteosarcomas, soft tissue sarcomas
  • a further aspect of the invention concerns the use of a diagnostic composition of the invention for the diagnosis of a disease selected from the group of proliferative diseases, immune diseases, infectious diseases, vascular diseases, rheumatoid diseases, and inflammatory diseases.
  • Fig. 1 Cryoelectron microscopy of AVE9.
  • Fig. 3 Binding of AVE 9 and AVE3 to various tumor cell lines analyzed by flow cytometry using rhodamine-labeled liposomes.
  • Fig. 4 Pharmacokinetics of free doxorubicin and doxorubicin encapsulated into AVE9 or AVE95 in comparison to Doxil.
  • Fig. 5 Antitumor effects of doxorubicin encapsulated into AVE9 or AVE95 in comparison to unencapsulated doxorubicin.
  • C26 tumor-bearing mice were injected three-times (day 1, 3, and 6) with doxorubicin at 4 g/kg body weight.
  • Fig. 6 Comparison of antitumor effects of AVE95-dox with pegylated liposomes (Doxil). C26 tumor-bearing mice were injected three-times (day 1, 3, and 6) with doxorubicin at 4 mg/kg body weight.
  • Fig. 7 Antitumor effects of AVE95-dox and liposomes composed of 30 mol% SM, 50 mol% cholesterol and 20 mol% PC (30/50-dox) containing entrapped doxorubicin. C26 tumor-bearing mice were injected three-times (day 1, 3, and 6) with doxorubicin at 4 mg/kg body weight.
  • Fig. 8 Pharmacokinetics of free mitoxantrone and mitoxantrone encapsulated into AVE95.
  • Fig. 9 Antitumor effects of AVE95-mitoxantrone on C26 colon carcinoma tumors using a mitoxantrone dose of 4 mg/kg body weight injected at day 1, 3 and 6.
  • Example 1 AVE9 are long-circulating liposomes
  • AVE3 (33.3 mol% cholesterol, DLPE, DOPS) highly negatively charged liposomes
  • AVE5 (33.3 mol% cholesterol, DLPE, DOPG) highly negatively charged liposomes
  • AVE7 35 mol% cholesterol, 15.4 mol% egg PC, 14.7 mol% DLPE, 16.7 mol% DOPS, 18.2 mol% milk SM
  • AVE9 35 mol% cholesterol, 32,1 mol% POPC, 14,7 mol% DLPE, 18.2 mol% milk SM
  • AVE11 35 mol% cholesterol, 28,8 mol% POPC, 14,7 mol% DLPE, 3,4 mol% DOPS, 18.2 mol% milk SM
  • AVE14 (33.3 mol% cholesterol, 33.3 mol% egg PC, 33.3 mol% DLPE).
  • lipids were purchased from Avanti Polar Lipids (USA) and were used without further purification. Liposomes were prepared from dried lipid films by hydration. For this purpose lipids were dissolved in chloroform or chloroform/methanol (1:1) and mixed at the indicated ratios. For pharmacokinetic studies tritium-labeled cholesteryloleoylether (10 ⁇ Ci/ ⁇ mol lipid) was added. Lipids were dried using a rotary evaporator and residual solvent was removed under high vacuum. Lipid films were then hydrated with 10 mM Tris-HCl pH 7.4 to a final lipid concentration of 10 ⁇ mol/ml. Liposomes were extruded 21- times through 50 nm membranes.
  • All liposomes prepared had an average size of 80 - 110 nm. Average zeta potentials were -67 mV for AVE3, -43 mV for AVE5, -49 mV for AVE7, -8 mV for AVE9, and -12 mV for AVE14.
  • Liposomes (1 ⁇ ol lipid in PBS) were injected i.v. into the tail veins of nude mice. Blood samples were taken at varying time points and analyzed for radioactivity by scintillation counting. For the analysis of tumor and organ accumulation liposomes were injected into nude mice bearing established subcutaneous murine C26 colon carcinomas. This study showed that AVE3, AVE5 and AVE7 were rapidly cleared from circulation (50% value ⁇ 5 min). Prolonged circulation times were observed for AVE9 (50% value approx. 70 - 80 min), AVE11 (50% value approx. 10 min), and AVE14 (50% value approx. 30 min). Thus, liposomes based on the AVE9 lipid composition showed a highly extended circulation in the blood stream.
  • a 500 mesh copper grid was coated using 5 ⁇ l of the liposomal preparation. After removing the supernatant the sample was frozen in ethane at ⁇ 170°C. The grid was transferred to a liquid nitrogen cooled grid holder and examined in an electron microscope. AVE9 liposomes appeared as slightly oval and mainly unilamellar structures with a size between 50 - 200 nm (Fig. 1).
  • Example 3 Stability of empty AVE9 liposomes After preparation of AVE9 liposomes as described in example 1 , liposomes were stored at 4 - 8°C and particle size was analyzed weekly for up to 120 days by photon correlation spectroscopy (PCS). No increase in particle size was observed over this period of time indicating that AVE9 liposomes are stable under storage conditions.
  • PCS photon correlation spectroscopy
  • Example 4 AVE9 liposomes show no or only weak binding to plasma proteins
  • AVE9 liposomes were analyzed using a hemolytic complement assay (plates with agarose-fixed sensitized sheep erythrocytes). AVE3 were included in these experiments as liposomes showing strong binding of plasma proteins. For this purpose liposomes at a concentration of 0,5 to 16 nmol lipid were incubated with human serum. AVE3 at a concentration between 2 to 16 nmol showed strong binding of complement factors as indicated by an inhibition of complement- mediated lysis. In contrast, AVE9 did not bind complement factors at the applied lipid concentrations further demonstrating that AVE9 show no or only weak interaction with plasma proteins.
  • Example 6 Cell binding properties of AVE9 liposomes
  • AVE9 liposomes The binding properties of AVE9 liposomes to various tumor cell lines (human melanoma cell lines Me Wo, B254 and MSM, human lung carcinoma cell line A549, rat glioblastoma cell line C6) was analyzed with rhodamine-labeled liposomes containing 0,3 mol% Rh- DPPE in the lipid bilayer. Liposomes were prepared as described in example 1. AVE3 liposomes were included to compare binding of AVE9 liposomes with that of highly negatively charged liposomes. Tumor cells were incubated with liposomes (100 nmol lipid) at 4°C for 30 min and subsequently analyzed by flow cytometry for cell binding activity.
  • liposomes containing between 10 to 50 mol% cholesterol were prepared: AVE9 (35 mol% cholesterol, 32,1 mol% POPC, 14.7 mol% DLPE, 18.2 mol% bovine milk SM), AVE91 (10 mol% cholesterol, 44,4 mol% POPC, 20,4 mol% DLPE, 25,2 mol% bovine milk SM), AVE92 (20 mol% cholesterol, 39,5 mol% POPC, 18,1 mol% DLPE, 22,2 mol% bovine milk SM), AVE93 (30 mol% cholesterol, 34,6 mol% POPC, 15,8 mol% DLPE, 19,6 mol% bovine milk SM), AVE94 (40 mol% cholesterol, 29,6 mol% POPC, 13,6 mol% DLPE, 16,8 mol% bovine milk SM), and AVE95 (50
  • cholesteryloleoylether (10 ⁇ Ci/ ⁇ mol lipid) was incorporated into the lipid bilayer.
  • Liposomes were prepared from dried lipid films by hydration with 10 mM Tris-HCl pH 7.4 as described in example 1. All liposomes had similar zeta potentials, which were in the range of -8 to -3 mV. Particle sizes ranged from 70 nm for AVE91 to 105 nm for AVE95, indicating that particle size slightly increased with increasing cholesterol concentrations.
  • Liposomes (1 ⁇ mol lipid in PBS) were injected i.v. into the tail veins of nude mice.
  • Example 8 Influence of spingomyelin and phosphatidylethanolamine on pharmacokinetics of AVE9 liposomes
  • AVE9-0SM 35 mol% cholesterol, 50,3 mol% POPC, 14,7 mol% DLPE
  • AVE9-5SM 35 mol% cholesterol, 45,3 mol% POPC, 14,7 mol% DLPE, 5 mol% milk SM
  • AVE9-30SM 35 mol% cholesterol, 20,3 mol% POPC, 14,7 mol% DLPE, 30 mol% milk SM
  • AVE9-0PE 35 mol% cholesterol, 46,8 mol% POPC, 18.2 mol% milk SM.
  • Example 9 Influence of pegylation on pharmacokinetics of AVE9 liposomes
  • the effects of pegylation on pharmacokinetics of AVE9 was analyzed for AVE9- 5%PEG5000 (33,2 mol% cholesterol, 30,5 mol% POPC, 14 moI% DLPE, 17,3 mol% bovine milk SM, 5 mol% DPPE-PEG5000) and AVE9-0SM/5%PEG5000 (33,2 mol% cholesterol, 47,8 mol% POPC, 14 mol% DLPE, 5 moI% DPPE-PEG5000) in comparison to AVE9 and other formulations described in example 3.
  • Liposomes were prepared and analyzed for pharmacokinetic properties as described in example 1.
  • Example 10 Encapsulation of doxorubicin into AVE9 and AVE95
  • Doxorubicin was encapsulated into AVE9 or AVE95 liposomes (see examples 1 and 7).
  • lipid films were hydrated with 300 mM citrate buffer pH 4.0. After extrusion the pH of the external aqueous solution was adjusted to pH 7.4 with NaOH. Liposomes were heated to 60°C and doxorubicin in PBS was added and incubated for 15 min. A drug to lipid ratio of 1 :5 (w vy) was routinely used in these experiments. Unencapsulated doxorubicin was removed by ultrafiltration using Vivaspin columns. Encapsulation efficiency was determined by reverse-phase HPLC analysis. By this approach approximately 70-90% of doxorubicin could be routinely encapsulated.
  • AVE9-dox and AVE95-dox were injected i.v. into the tail veins of nude mice and blood concentration of doxorubicin was determined by HPLC at varying time points.
  • doxorubicin was determined by HPLC at varying time points.
  • doxorubicin was encapsulated into pegylated "stealth liposomes" (Doxil ® ).
  • Doxil ® pegylated "stealth liposomes”
  • Example 12 Pharmacodynamics of AVE9 and AVE95-doxorubicin liposomes
  • pharmacodynamic experiments in a C26 murine colon carcinoma model were performed.
  • tumor cells were injected subcutaneously into nude mice. After tumors had reached a size of approximately 50-100 mm 3 tumor-bearing mice were treated with doxorubicin-loaded liposomes injecting a doxorubicin dose of 4 mg/kg body weight at days 1, 3 and 6.
  • AVE9-dox and AVE95-dox were compared to unencapsulated doxorubicin.
  • this experiment we observed reduced tumor growth and a prolonged survival time for animals treated with AVE95-dox compared to animals treated with AVE9-dox or free doxorubicin. All animals showed reduced tumor growth compared to untreated control animals (Fig. 5).
  • AVE95-dox was compared to Doxil ® for the treatment of C26 tumors applying a dose of 4 mg/kg. Compared to Doxil administration of AVE95-dox resulted in a statistically reduced tumor growth (p ⁇ 0.05) and a prolonged survival time (Fig. 6).
  • AVE95-dox liposomes were compared to a AVE95-based formulation containing varying sphingomyelin concentrations. Firstly, AVE95-dox was compared to the same formulation in which sphingomyelin was substituted by phosphatidylcholine (AVE95-0SM-dox). The removal of sphingomyelin drastically reduced efficacy to that seen with free doxorubicin. Secondly, AVE95-dox was compared to liposomes consisting of 50 mol% cholesterol, 30 mol% sphingomyelin and 20 mol% phosphatidylcholine.
  • this formulation contained the same cholesterol concentration but approximately twice as much sphingomyelin as AVE95 liposomes.
  • a reduced antitumor activity was observed for liposomes containing 30 mol% sphingomyelin compared to AVE95 containing only 14 moI% sphingomyelin demonstrating that AVE95 are superior over the high SM-concentration type of liposomes (Fig. 7).
  • Example 13 Encapsulation of mitoxantrone into AVE9 liposomes
  • Mitoxantrone was encapsulated into AVE9 or AVE95 liposomes (see examples 1 and 7) by remote loading (Mayer et al. (1986) Chem. Phys. Lipids 40:333-345). For this purpose lipid films were rehydrated with 300 mM citrate buffer pH 4.0. After extrusion the pH of the external aqueous solution was adjusted to pH 7.4 with 2 N NaOH. Liposomes were heated to 55°C and mitoxantrone in PBS was added and incubated for 15 min. A drug to lipid ratio of 1:10 (w/w) was routinely used in these experiments. Unencapsulated mitoxantrone was removed by ultrafiltration using Vivaspin columns.
  • Encapsulation efficiency was determined by reverse-phase HPLC analysis. By this approach approximately 75-85% of mitoxantrone could be routinely encapsulated. No differences in encapsulation efficiency were observed for AVE9 and AVE95. AVE95-MXR were stable upon storage at 8°C with only marginal drug leakage over a period of 4 weeks.
  • Example 14 Pharmacokinetics AVE95-encapsulated mitoxantrone
  • Efficacy of AVE95-MRX was analyzed in a C26 murine colon carcinoma model.
  • tumor cells were injected subcutaneously into nude mice. After tumors had reached a size of approximately 50-100 mm 3 , tumor-bearing mice were treated with mitoxantrone-loaded liposomes injecting a mitoxantrone dose of 1.5 mg/ml or 4 mg/kg body weight at days 0, 2 and 5. Unencapsulated mitoxantrone was included in these experiments. At a mitoxantrone dose of 4 mg/kg a strong inhibition of tumor growth was observed for both free and encapsulated mitoxantrone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne de nouveaux vecteurs d'administration de médicaments, leur production et leur application.
EP04819663A 2003-12-04 2004-12-06 Vecteurs d'administration de medicaments et leurs applications Withdrawn EP1689365A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04819663A EP1689365A1 (fr) 2003-12-04 2004-12-06 Vecteurs d'administration de medicaments et leurs applications

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03027944A EP1537858A1 (fr) 2003-12-04 2003-12-04 Vécteurs pour l'administration de médicaments et leurs utilisations
PCT/EP2004/013861 WO2005053642A1 (fr) 2003-12-04 2004-12-06 Vecteurs d'administration de medicaments et leurs applications
EP04819663A EP1689365A1 (fr) 2003-12-04 2004-12-06 Vecteurs d'administration de medicaments et leurs applications

Publications (1)

Publication Number Publication Date
EP1689365A1 true EP1689365A1 (fr) 2006-08-16

Family

ID=34442962

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03027944A Withdrawn EP1537858A1 (fr) 2003-12-04 2003-12-04 Vécteurs pour l'administration de médicaments et leurs utilisations
EP04819663A Withdrawn EP1689365A1 (fr) 2003-12-04 2004-12-06 Vecteurs d'administration de medicaments et leurs applications

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP03027944A Withdrawn EP1537858A1 (fr) 2003-12-04 2003-12-04 Vécteurs pour l'administration de médicaments et leurs utilisations

Country Status (5)

Country Link
EP (2) EP1537858A1 (fr)
JP (1) JP2007513122A (fr)
AU (1) AU2004294724A1 (fr)
CA (1) CA2544890A1 (fr)
WO (1) WO2005053642A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101632639B (zh) * 2009-06-03 2011-01-19 邓菊娟 替硝唑脂质体注射剂及其制备方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
CN100450544C (zh) * 2005-12-19 2009-01-14 南方医科大学 一种用于治疗股骨头坏死的复合制剂
CN101389356B (zh) * 2006-01-06 2012-09-05 武冈真司 药物输送物质
WO2007088952A1 (fr) * 2006-01-31 2007-08-09 Taiho Pharmaceutical Co., Ltd. Preparation de liposome comprenant une substance ayant une action anticancereuse
EP2004177B1 (fr) 2006-03-16 2012-01-25 Women and Infants Hospital of Rhode Island Inc. Composes de nitrofurane utilises dans le traitement du cancer et de l'angiogenese
US8415453B2 (en) * 2007-02-13 2013-04-09 Academia Sinica Lung cancer-targeted peptides and applications thereof
US8088887B2 (en) 2007-02-13 2012-01-03 Academia Sinica Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment
EP2184355A4 (fr) * 2007-08-09 2011-04-27 Daiichi Sankyo Co Ltd Anticorps modifié par une molécule hydrophobe
CN100525833C (zh) * 2007-09-21 2009-08-12 南京大学 右旋糖苷40/多肽冻干粉针剂成型的方法
CN104622809B (zh) * 2008-05-23 2019-04-19 英属哥伦比亚大学 用于脂质体纳米颗粒的修饰的药物
WO2010061881A1 (fr) 2008-11-26 2010-06-03 中外製薬株式会社 Ologoribonucléotide ou acide nucléique de peptide capable d'inhiber l'activité du virus de l'hépatite c
WO2010061880A1 (fr) * 2008-11-26 2010-06-03 中外製薬株式会社 Préparation vésiculaire
CN102497887A (zh) 2009-04-17 2012-06-13 Isis创新公司 递送遗传物质的组合物
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
JP2011246464A (ja) * 2010-04-28 2011-12-08 Wakamoto Pharmaceutical Co Ltd ジクロフェナクナトリウムを封入した後眼部到達用ポリマーコーティングリポソーム
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
CN101874781B (zh) * 2010-07-20 2012-03-07 中南大学 疏水改性葡聚糖修饰的长循环脂质体及其制备方法
CN101966161B (zh) * 2010-09-06 2012-05-23 海南美兰史克制药有限公司 一种雷贝拉唑钠脂质体肠溶片
CN102309451B (zh) * 2011-09-14 2012-11-21 海南美兰史克制药有限公司 硝呋太尔脂质体固体制剂
WO2013059922A1 (fr) * 2011-10-25 2013-05-02 The University Of British Columbia Nanoparticules lipides de taille limite, et procédés correspondants
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
CN103371975A (zh) * 2012-04-16 2013-10-30 上海现代药物制剂工程研究中心有限公司 靶向长循环脂质体制剂及其制备方法
CN102885765B (zh) * 2012-10-25 2013-11-06 哈药集团生物工程有限公司 一种盐酸伊立替康注射液及其制备方法
CA2906732C (fr) 2013-03-15 2023-08-08 The University Of British Columbia Nanoparticules lipidiques pour la transfection et procedes associes
EP3139964B1 (fr) * 2014-05-06 2019-04-24 Memorial Sloan Kettering Cancer Center Système de support magnéto-enzymatique pour l'imagerie et l'administration ciblée et la libération d'agents actifs
CN105543161B (zh) * 2014-10-31 2019-08-02 陕西艾美雅生物科技有限公司 复合生物活性因子脂质体及其制备方法
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
CN108743953B (zh) * 2018-06-13 2021-06-01 四川大学 一种双重脑肿瘤靶向脂质材料及其应用
CN110711178A (zh) * 2018-07-11 2020-01-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途
IT202000007228A1 (it) * 2020-04-06 2021-10-06 Diego Dolcetta SOMMINISTRAZIONE DI INIBITORI DI mTOR NEL SISTEMA NERVOSO CENTRALE
CN111686263B (zh) * 2020-08-10 2021-11-02 黑龙江中医药大学 一种增强下肢动脉硬化超声诊断的靶向超声造影剂及其制备方法
CN112451487B (zh) * 2020-12-07 2022-10-11 沈阳药科大学 一种姜黄素主动载药脂质体及其制备方法
KR20220150361A (ko) * 2021-02-26 2022-11-10 씨큐어 타이완 씨오., 엘티디. 티오퓨린계 화합물, 조성물, 제조 방법 및 용도
CN113694213A (zh) * 2021-08-20 2021-11-26 锦州医科大学 负载基因诊断探针和/或抗肺纤维化药物的纳米制剂及其制备方法
CN115197899B (zh) * 2022-07-20 2023-06-30 淮阴工学院 一种可调控内皮祖细胞分化趋势涂覆层的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005053642A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101632639B (zh) * 2009-06-03 2011-01-19 邓菊娟 替硝唑脂质体注射剂及其制备方法

Also Published As

Publication number Publication date
CA2544890A1 (fr) 2005-06-16
WO2005053642A1 (fr) 2005-06-16
EP1537858A1 (fr) 2005-06-08
JP2007513122A (ja) 2007-05-24
AU2004294724A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
EP1537858A1 (fr) Vécteurs pour l'administration de médicaments et leurs utilisations
EP1323415B1 (fr) Procede de revetement de particules fines avec un film de lipides
CA2067178C (fr) Methode et composition pour le traitement des tumeurs solides
KR100387561B1 (ko) 활성제제의조절방출을위한다중소포성리포솜의제법
YADAV Drug Delivery Reviews
US9999596B2 (en) Controlled release hydrogels
DD239117A5 (de) Verfahren zur herstellung von pharmazeutische zusammensetzungen auf liposomenbasis mit synthetischen phospholipiden als lipikomponenten
US11318097B1 (en) ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
EP1538164A1 (fr) Production et utilisation de péptides RGD
EP0160286B1 (fr) Liposomes
US20140186434A1 (en) Anti-tumor necrosis factor alpha (tnf-a) antibody used as a targeting agent to treat arthritis and other diseases
WO2006049307A1 (fr) Liposome et méthode d’injection d’une substance dans une cellule à l’aide dudit liposome
Charumathy et al. Recent update on liposome-based drug delivery system
JPWO2005021012A1 (ja) ゲムシタビン封入薬剤担体
KR100996975B1 (ko) 혈류 내 순환시간 증가를 위한 단백질로 수식된 리포솜 및이의 제조방법
Shivhare et al. A Review on Liposomes as a Novel Drug Delivery System
Kandpal et al. An updated review on niosomes: a promising drug carrier
JPH1029930A (ja) 閉鎖小胞の製造方法
CN104000781B (zh) 氨柔比星脂质体及其制备方法
KR100768265B1 (ko) 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
CN113384706A (zh) 用于治疗乙肝的缀合物、脂质基药物组合物及其制备方法和用途
CN113491774A (zh) 用于治疗乙肝的肝靶向缀合物、脂质基药物组合物及其制备方法和用途
US20130115270A1 (en) Anti-interleukin-1 (IL-1) antibody used as a targeting agent to treat arthritis and other diseases
PL197938B1 (pl) Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060510

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NAHDE, THOMAS

Inventor name: HOELLIG, PETER

Inventor name: MUELLER, ROLF

Inventor name: HILKA, TANJA

Inventor name: GRASER, ANDREAS

Inventor name: MUELLER-BRUESSELBACH, SABINE

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070703